Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: cacmed who wrote (10396)	6/6/2018 8:33:09 PM
From: donpat	Read Replies (1) \| Respond to of 12871

Know how! Without it anyone interested in picking up the "pieces" wouldn't have a clue. So, if this is to be a success it will be from/with NNVC and no one else.

To: cacmed who wrote (10396)	6/7/2018 1:23:33 PM
From: HardToFind	Read Replies (1) \| Respond to of 12871

What motivation would there be for the new money to want to save the current investors? You bring up a very good point. The current shareholder arrangement is a terrible deal for shareholders. Having Dr. Diwan essentially negotiate with himself on the original TheraCour licensing deal (after the original financing had been captured) did not work out at all well for the shareholders. Under the current circumstances, a venture finance person would do well to wait for the other shoe to drop and negotiate a new deal with TheraCour and Diwan alone, rather than buy into the current lousy deal. The one alternative that could change this situation would be for TheraCour and NNVC to renegotiate the terms of the licensing arrangement to something fair, in advance of negotiating for additional equity financing. That would not only enhance Diwan's reputation as an ethical businessman, but would additionally give would-be venture financing a reason to sign up for equity financing alongside the current shareholders. At the last shareholder meeting one insider told me the company needs to be restructured (unsolicited on my part). I don't know if the statement of "need" was relative to selling the company or was just for the company's survival. Personally, I think it would be needed for either. Because I had been repeatedly complaining about the 15% royalty on revenues and its potential impact on the company, at one point Dr. Seymour hinted to me that a TheraCour license restructuring "might" be in the works. (Then he abruptly retired.) I don't know where that sits. It may be dead.